Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP).

Abstract

BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a correct allergic evaluation allows identifying patients at risk of developing an anaphylactic reaction. Risk assessment of allergic reactions to COVID-19 vaccines is useful to limit contraindications to vaccination and help to safely vaccinate people supposed to be at risk of allergic reactions.

• Authors: Elio Novembre, Mariangela Tosca, Carlo Caffarelli, Mauro Calvani, Fabio Cardinale, Riccardo Castagnoli, Elena Chiappini, Claudio Cravidi, Michele Miraglia Del Giudice, Marzia Duse, Amelia Licari, Sara Manti, Alberto Martelli, Giampaolo Ricci, Giuseppe Pingitore, Gian Luigi Marseglia
• Journal: Italian journal of pediatrics (Ital J Pediatr) Vol. 48 Issue 1 Pg. 76 (May 16 2022) ISSN: 1824-7288 [Electronic] England
• PMID: 35578294 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s).

Chemical References

• COVID-19 Vaccines
• RNA, Messenger
• BNT162 Vaccine

Topics

• Anaphylaxis
• Asthma
• BNT162 Vaccine
• COVID-19 (epidemiology, prevention & control)
• COVID-19 Vaccines (adverse effects)
• Child
• Consensus
• Humans
• RNA, Messenger
• SARS-CoV-2